維亞生物(01873.HK)2022年收入23.8億元 同比增長約13.1%
格隆匯3月30日丨維亞生物(01873.HK)公吿,2022年度,公司累計服務客户數量增加至2,076家,報吿期全年集團收入由去年同期人民幣2,104.1百萬元持續增加至人民幣2,379.6百萬元,較去年同期增幅約為13.1%,毛利由去年人民幣651.0百萬元持續增加至人民幣815.7百萬元,較去年同期增幅約為25.3%。
集團經調整非國際財務報吿準則淨利潤由去年同期人民幣321.1百萬元下降至經調整非國際財務報吿準則淨虧損人民幣133.9百萬元。主要歸因於市場波動導致集團投資孵化企業的股權價值產生公允價值變動損失;中國內地COVID-19疫情反覆所導致的人員利用率下降;培育處於早期階段的新業務對利潤會產生一定程度的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.